CME-Pod Mon, 18 May 2026 17:00:56 -0400 https://www.buzzsprout.com/2322369 en-us © 2026 CME-Pod yes 9a50892e-5964-5b69-a443-df5997b43c1c Cornerstone Medical Education episodic false Designed by clinicians for clinicians, the Cornerstone Medical Education Podcast - that is, CME-Pod - meets busy healthcare providers right where they're at: in the trenches of patient care and on-the-go. Engaging and succinct, CME-Pod offers the latest data and incisive guidance from top experts, all with a concerted focus on advancing clinical practice and improving care for patients.

]]> Buzzsprout (https://www.buzzsprout.com) Cornerstone Medical Education https://storage.buzzsprout.com/x4njwogt84ruyg3xeuwem39eb1qm?.jpg CME-Pod Mitigating Chemotherapy-Induced Myelosuppression in ES-SCLC: An Expert Roadmap for Optimizing Clinical and Patient-Reported Outcomes Mitigating Chemotherapy-Induced Myelosuppression in ES-SCLC: An Expert Roadmap for Optimizing Clinical and Patient-Reported Outcomes This educational session, which was recorded during our Grand Rounds series conducted in 2025-2026 with Dr. Martin Dietrich, affords learners a timely and succinct overview of the rapidly evolving ES-SCLC treatment landscape, with a keen focus on the best practice mitigation and management of chemotherapy-induced myelosuppression (CIM), a major challenge in ES-SCLC care. More specifically, Dr. Dietrich dives into practical pearls of proactive strategies for achieving multilineage myeloprotection in patients living with ES-SCLC, and in so doing, not only improving their clinical outcomes, but also their quality-of-life.

To access the slides, the bibliography, and our Cornerstone Clinical Tool for this activity, please visit our website here: https://cornerstonemeded.com/educational-programs/_es-sclc/. 

]]> This educational session, which was recorded during our Grand Rounds series conducted in 2025-2026 with Dr. Martin Dietrich, affords learners a timely and succinct overview of the rapidly evolving ES-SCLC treatment landscape, with a keen focus on the best practice mitigation and management of chemotherapy-induced myelosuppression (CIM), a major challenge in ES-SCLC care. More specifically, Dr. Dietrich dives into practical pearls of proactive strategies for achieving multilineage myeloprotection in patients living with ES-SCLC, and in so doing, not only improving their clinical outcomes, but also their quality-of-life.

To access the slides, the bibliography, and our Cornerstone Clinical Tool for this activity, please visit our website here: https://cornerstonemeded.com/educational-programs/_es-sclc/. 

]]> Cornerstone Medical Education Buzzsprout-19198772 Mon, 18 May 2026 17:00:00 -0400 2766 1 4 full false 2025 HFSA Symposium - The Evolving Treatment Landscape in ATTR 2025 HFSA Symposium - The Evolving Treatment Landscape in ATTR Originally presented as a satellite symposium at the 2025 HFSA Annual Scientific Meeting in Minneapolis, this educational activity is targeted to cardiologists, neurologists, heart failure specialists, and the interprofessional team of nurse practitioners and cardiac nurses that help manage patients with transthyretin-mediated amyloidosis (ATTR). Designed as both a data intensive and a case-based practicum, this session will offer learners an expert-led appraisal of the evolving clinical trial evidence and regulatory updates for novel therapeutics in ATTR, with an emphasis on clinical best practices for treatment selection and sequencing in ATTR-CM, ATTR-PN, and ATTR of mixed phenotype, and will include an intensive review of established and emerging pharmacologic mechanisms and incisively examine how they interface with ATTR pathophysiology. 

CME-Pod listeners will also get a unique “glimpse beyond the cutting edge of the calculus” in a segment led by the two winners of the 1st Annual (2024) ATTR Early-Career Research Forum, in which they detail the rationale, design, results, and real-world promise of their original ATTR research projects. Finally, the session will be punctuated by an interactive and dynamic case-based discussion that equips and engages cardiologists, neurologists, and other members of the ATTR multidisciplinary and interprofessional treatment team to bridge the disconnect between clinician and patient expectations, with the overarching strategic goal of harmonizing shared decision-making, optimizing evidence-based treatment decisions, and improving outcomes across the ATTR disease continuum.

To obtain CE credit for listening, complete the activity pre-test here: https://form.jotform.com/AcademyCME/24C15Pre

After the session, complete the post-test, activity evaluation, and CE credit request here: https://form.jotform.com/AcademyCME/24C15post

Thank you for listening to CME-Pod! We at Cornerstone hope it equips you to improve your clinical practice and better serve your patients.

]]> Originally presented as a satellite symposium at the 2025 HFSA Annual Scientific Meeting in Minneapolis, this educational activity is targeted to cardiologists, neurologists, heart failure specialists, and the interprofessional team of nurse practitioners and cardiac nurses that help manage patients with transthyretin-mediated amyloidosis (ATTR). Designed as both a data intensive and a case-based practicum, this session will offer learners an expert-led appraisal of the evolving clinical trial evidence and regulatory updates for novel therapeutics in ATTR, with an emphasis on clinical best practices for treatment selection and sequencing in ATTR-CM, ATTR-PN, and ATTR of mixed phenotype, and will include an intensive review of established and emerging pharmacologic mechanisms and incisively examine how they interface with ATTR pathophysiology. 

CME-Pod listeners will also get a unique “glimpse beyond the cutting edge of the calculus” in a segment led by the two winners of the 1st Annual (2024) ATTR Early-Career Research Forum, in which they detail the rationale, design, results, and real-world promise of their original ATTR research projects. Finally, the session will be punctuated by an interactive and dynamic case-based discussion that equips and engages cardiologists, neurologists, and other members of the ATTR multidisciplinary and interprofessional treatment team to bridge the disconnect between clinician and patient expectations, with the overarching strategic goal of harmonizing shared decision-making, optimizing evidence-based treatment decisions, and improving outcomes across the ATTR disease continuum.

To obtain CE credit for listening, complete the activity pre-test here: https://form.jotform.com/AcademyCME/24C15Pre

After the session, complete the post-test, activity evaluation, and CE credit request here: https://form.jotform.com/AcademyCME/24C15post

Thank you for listening to CME-Pod! We at Cornerstone hope it equips you to improve your clinical practice and better serve your patients.

]]> Cornerstone Medical Education Buzzsprout-18283169 Mon, 01 Dec 2025 21:00:00 -0500 5340 1 3 full false Closing Chasms and Optimizing Care in Hereditary Hemorrhagic Telangiectasia: Expert Perspectives on the Role of Intravenous Iron in the Management of HHT-Associated IDA Closing Chasms and Optimizing Care in Hereditary Hemorrhagic Telangiectasia: Expert Perspectives on the Role of Intravenous Iron in the Management of HHT-Associated IDA To take the post-test and claim your CE credit for this session, please visit: https://online.epocrates.com/contextuallink/cme/activity/OQUMHW

This educational initiative is targeted to the community-based multidisciplinary and interprofessional HHT treatment team of primary care physicians, internists, hematologists, oncologists, gastroenterologists, otorhinolaryngologists, allergists, and nurses/nurse practitioners, pharmacists, and physician assistants. Strategically developed to promote community clinician awareness of HHT and galvanize optimization of HHT-associated ID and IDA management, this episode will begin with an overview of HHT epidemiology and pathophysiology, emphasizing diverse disease manifestations and clinical presentation, then move into an appraisal of current guideline recommendations for diagnosing, screening, and treating HHT-associated IDA, with an incisive focus on the role of intravenous (IV) iron as iron replacement therapy. Practical differentiators between currently-available IV iron products, inclusive of total dose infusion (TDI) capacity and relative risk for IV iron-induced hypophosphatemia, will be highlighted and emphasized throughout the activity using practical patient case scenarios.

]]> To take the post-test and claim your CE credit for this session, please visit: https://online.epocrates.com/contextuallink/cme/activity/OQUMHW

This educational initiative is targeted to the community-based multidisciplinary and interprofessional HHT treatment team of primary care physicians, internists, hematologists, oncologists, gastroenterologists, otorhinolaryngologists, allergists, and nurses/nurse practitioners, pharmacists, and physician assistants. Strategically developed to promote community clinician awareness of HHT and galvanize optimization of HHT-associated ID and IDA management, this episode will begin with an overview of HHT epidemiology and pathophysiology, emphasizing diverse disease manifestations and clinical presentation, then move into an appraisal of current guideline recommendations for diagnosing, screening, and treating HHT-associated IDA, with an incisive focus on the role of intravenous (IV) iron as iron replacement therapy. Practical differentiators between currently-available IV iron products, inclusive of total dose infusion (TDI) capacity and relative risk for IV iron-induced hypophosphatemia, will be highlighted and emphasized throughout the activity using practical patient case scenarios.

]]> Cornerstone Medical Education Buzzsprout-15166204 Thu, 30 May 2024 16:00:00 -0400 3973 full false Optimizing Outcomes for Patients with DOAC-Related Bleeding: A Multidisciplinary Appraisal of Data-Driven Management Strategies Using Specific Reversal Agents Optimizing Outcomes for Patients with DOAC-Related Bleeding: A Multidisciplinary Appraisal of Data-Driven Management Strategies Using Specific Reversal Agents In this episode of CME-Pod, leading clinical experts - Drs. Truman Milling, Jr, Deborah Siegal, and Geoffrey Barnes - will provide learners with a circumscription of the clinical benefits and risks associated with DOAC usage, inclusive of patient-specific, disease-specific, and drug-specific risk factors, and will examine the unique pharmacologic mechanisms of established and emerging specific reversal therapeutics. A review of the evidentiary base will follow, encompassing completed, ongoing, and planned clinical trials for specific reversal agents, as well as recent readouts and pending regulatory updates that have the potential to meaningfully shift the calculus. The session will conclude with a case-based segment that tangibly highlights the imperative need for multidisciplinary collaboration and the importance of individualized, data-driven treatment selection.

To access the webinar on Healio, complete the post-test and activity evaluation, and claim your CE credit, please follow this link: https://cme.healio.com/cardiology/20240112/optimizing-outcomes-for-patients-with-doac-related-bleeding

]]> In this episode of CME-Pod, leading clinical experts - Drs. Truman Milling, Jr, Deborah Siegal, and Geoffrey Barnes - will provide learners with a circumscription of the clinical benefits and risks associated with DOAC usage, inclusive of patient-specific, disease-specific, and drug-specific risk factors, and will examine the unique pharmacologic mechanisms of established and emerging specific reversal therapeutics. A review of the evidentiary base will follow, encompassing completed, ongoing, and planned clinical trials for specific reversal agents, as well as recent readouts and pending regulatory updates that have the potential to meaningfully shift the calculus. The session will conclude with a case-based segment that tangibly highlights the imperative need for multidisciplinary collaboration and the importance of individualized, data-driven treatment selection.

To access the webinar on Healio, complete the post-test and activity evaluation, and claim your CE credit, please follow this link: https://cme.healio.com/cardiology/20240112/optimizing-outcomes-for-patients-with-doac-related-bleeding

]]> Bryan Taylor Buzzsprout-14626892 Mon, 04 Mar 2024 15:00:00 -0500 3911 1 1 full false